1. Medtech Insight
  2. >>Archive

News In Brief

Volcano buys Crux Biomedical. Medtronic/Weigao joint venture ends. Edwards Lifesciences updates Sapien growth targets. More news briefs.

Volcano Corp. will enter the peripheral therapeutics market by acquiring privately held Crux Biomedical Inc.for $36 million, plus milestone payments, under an agreement announced Dec. 3. The Crux VCF inferior vena cava filter system gained 510(k) clearance in July and Volcano plans to seek regulatory approval to market the system in combination with its IVUS intravascular imaging technology. Crux VCF features a helical design that self-centers and allows bi-directional retrieval through either the femoral or jugular veins to treat pulmonary embolisms. Headquartered in Menlo Park, Calif., Crux Biomedical also gained European CE mark clearance for the device in December 2011. Volcano says it plans to commence sales of Crux products by the end of 2013. “A key element of our growth strategy is to diversify beyond coronary applications and increase penetration of the peripheral market with our imaging technology,” said Volcano CEO Scott Huennekens. The firm estimates the U.S. IVC filter market to be $300 million. (See Also see "New Products In Brief" - Medtech Insight, 23 July, 2012..)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Execs On The Move: 7-11 April 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 
• By Brian Bossetta

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 
• By Natasha Barrow

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.